Are the Pathological Characteristics of Prostate Cancer More Aggressive or More Indolent Depending upon the Patient Age?
Table 1
Clinical data of all 2929 patients in different age groups.
Total (2929)
Group 1 (133)
Group 2 (2033)
Group 3 (763)
Median Age (years)
71 (33–91)
52 (33–55)
69 (56–75)
79 (76–91)
Median tPSA (μg/dL)
19.0 (1.7–>1000)
20 (3.7–500)
18.0 (1.7–>1000)
20.7 (1.7–>1000)
Median BMI (kg/m2)
24.2 (15.1–41.7)
25.1 (18.0–32.5)
24.1 (16.4–40.1)
23.7 (15.1–41.7)
T stage
T1-T2
1490 (50.8%)
56 (42.1%)
1128 (55.5%)
306 (40.1%)
T3-T4
1439 (49.2%)
77 (57.9%)
905 (44.5%)
457 (59.9%)
N
0
2021 (68.9%)
90 (67.7%)
1450 (71.3%)
481 (63.0%)
1
908 (31.1%)
43 (32.3%)
583 (28.7%)
282 (37.0%)
M
0
1976 (67.5%)
86 (64.7%)
1423 (70.0%)
467 (61.2%)
1
953 (32.5%)
47 (35.3%)
610 (30.0%)
296 (38.8%)
Group 1: age ≤ 55 years (young men). Group 2: age 56–75 years (middle-aged and old men). Group 3: age > 75 years (very old men). tPSA: total prostate-specific antigen; BMI: body mass index.
